Related Experiment Video

Updated: Jul 11, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Harnessing tumor immunogenomics: Tumor neoantigens in ovarian cancer and beyond

Mengrui Wu1, Shengtao Zhou1

  • 1Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, PR China.

Biochimica Et Biophysica Acta. Reviews on Cancer
|November 7, 2023
PubMed

Insights

Immunotherapy shows promise for ovarian cancer treatment by targeting genomic alterations. Challenges remain in neoantigen-based therapies due to tumor heterogeneity, necessitating further research for personalized treatment strategies.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Ovarian cancer is a leading cause of gynecological cancer mortality due to its aggressive nature.
  • Immunotherapy offers targeted treatment options with potentially fewer side effects for ovarian cancer.
  • Genomic alterations identified through next-generation sequencing are crucial for developing effective immunotherapies.

Purpose of the Study:

  • To explore the role of immunogenomics in ovarian cancer treatment.
  • To identify genomic alterations as potential immunotherapy targets.
  • To address challenges in neoantigen-based immunotherapies for ovarian cancer.

Main Methods:

  • Utilizing next-generation sequencing to identify genomic alterations.
  • Investigating the impact of genetic alterations on cancer immune responses.
  • Analyzing immunogenomic data to understand treatment efficacy.

Main Results:

  • Genomic alterations are key targets for ovarian cancer immunotherapy.
  • Immunogenomics research highlights the importance of genetic changes in immune response.
  • Tumor heterogeneity and low mutation burden present challenges for neoantigen therapies.

Conclusions:

  • Neoantigen-based immunotherapies hold significant promise for ovarian cancer.
  • Further research is needed to identify neoantigen-specific tumor-infiltrating lymphocytes (TIL).
  • Personalized treatment strategies, refined neoantigen selection, and optimized combinations are crucial for improving patient outcomes.
Keywords:
ImmunogenomicsImmunotherapyNeoantigenNext-generation sequencingOvarian cancer

More Related Videos

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.3K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
380
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K